Brent Moody, MD: Assessing the Prognostic Significance of the 31-gene Expression Profile Test

Dr. Moody reviews findings from a poster presented at the 2025 Fall Clinical Dermatology Conference, highlighting the clinical utility of the 31-gene expression profile (31-GEP) test in patients with cutaneous melanoma. The study evaluated how this molecular test can help stratify melanoma-specific survival across different histological subtypes.

Topics Covered

• Overview of the 31-GEP test and its role in melanoma prognosis
• How gene expression profiling supports risk stratification
• Findings across multiple histological melanoma subtypes
• Implications for clinical decision-making and patient management

Reference
Marks E and Wysong A. The 31-gene expression profile test stratifies melanoma-specific survival across histological subtypes in patients with cutaneous melanoma. Presented at the 2025 Fall Clinical Dermatology Conference; October 23–26, 2025; Las Vegas, Nevada.

Explore Related Resources

• Identifying the Risk of Central Nervous System Metastasis Using the 31-Gene Expression Profile Test
• Risk Stratification of Patients with Stage I Cutaneous Melanoma Using 31-Gene Expression Profiling